Edition:
United States

ProQR Therapeutics NV (PRQR.OQ)

PRQR.OQ on NASDAQ Stock Exchange Global Market

2.85USD
3:59pm EST
Change (% chg)

$-0.10 (-3.39%)
Prev Close
$2.95
Open
$2.95
Day's High
$2.95
Day's Low
$2.85
Volume
3,545
Avg. Vol
28,877
52-wk High
$6.85
52-wk Low
$2.85

Summary

Name Age Since Current Position

Daniel De Boer

31 2012 Founding Chief Executive Officer

Gerard Platenburg

50 Co-Founder, Chief Innovation Officer

Smital Shah

2014 Chief Financial Officer

Rene Beukema

50 Chief Corporate Development Officer and General Counsel

David Rodman

2017 Chief Development Strategy Officer

Biographies

Name Description

Daniel De Boer

Mr. Daniel De Boer serves as Founding Chief Executive Officer of ProQR Therapeutics NV. He has been a serial entrepreneur in IT who has led a number of other companies through phases of growth, initiating development and launch of several IT related products in several European countries. Prior to founding ProQR, Daniel served as a founder and Chief Executive Officer of RNA Systems, founder and Chief Executive Officer of PC Basic, and founder and Chief Executive Officer of Running IT. Daniel is responsible for the overall strategy and general business in the company.

Gerard Platenburg

Mr. Gerard Platenburg is a Co-Founder, Chief Innovation Officer of ProQR Therapeutics NV. He served as the sole Member of the Company's Supervisory Board between August 2012 and December 2013. He has more than twenty years of senior managerial experience, which he gained during his different operational and leadership roles in growing biotech companies. Prior to joining the Company, Mr. Platenburg worked at Isa Pharmaceuticals B.V. from June 2009 to January 2014. Mr. Platenburg co-founded Prosensa Holding N.V., growing it to become a well-known RNA modulation clinical stage company, and held various positions between April 2002 and May 2009, including Chief Executive Officer and Chief Development Officer. Mr. Platenburg also worked at Pharming B.V. from April 1990 to March 2002. He is a passionate and driven pioneer of early stage technologies. Mr. Platenburg has a master degree in chemistry and molecular biology from Leiden University in 1987 and pursued PhD work at Leiden University.

Smital Shah

Ms. Smital Shah has served as Chief Financial Officer of ProQR Therapeutics NV, since October 2014. She has a 12-year track record of management and leadership in biopharma companies and investment banking, with particular experience in financial strategy and capital markets. Prior to joining the Company she was at Gilead Sciences, where she managed their multi-billion dollar debt, cash and investment portfolios. Prior to Gilead, she spent several years in investment banking at Leerink Partners and JP Morgan focused on capital raising and strategic transactions in the biotech space. Previously, she held various R&D focused roles at Johnson & Johnson. Ms. Smital Shah has a Bachelors and Masters in Chemical Engineering and an MBA from the University of California at Berkeley.

Rene Beukema

Mr. Rene K. Beukema serves as Chief Corporate Development Officer and General Counsel of ProQR Therapeutics NV. Mr. Beukema joined in September 2013 and is a seasoned in-house corporate lawyer in the Dutch biotechnology arena. Prior to joining us, Mr. Beukema served as general counsel and corporate secretary of Crucell N.V. for twelve years, following his experience as a senior legal counsel at GE Capital / TIP Europe and legal counsel at TNT Express Worldwide. Mr. Beukema was also a venture partner of Aescap Venture, a life sciences venture capital firm. Mr. Beukema is the co-founder and advisor of Mytomorrows N.V., a Dutch life sciences company, and a member of the VU Medical Cancer Center children in Amsterdam. He holds a post-doctoral degree in corporate law from the University of Nijmegen in co-operation with the Dutch Association of In-house Counsel (Nederlands Genootschap van Bedrijfsjuristen) and a Master’s degree in Dutch law from the University of Amsterdam.

David Rodman

Dr. David M. Rodman M.D., is Chief Development Strategy Officer of the Company. Dr. Rodman joined ProQR in March 2017 with extensive experience in rare disease drug development, translational medicine and RNA therapeutics, having previously served in leadership roles with Novartis Institute for Biomedical Research (NIBR), Vertex Pharmaceuticals, miRagen Therapeutics and Nivalis Therapeutics.

Basic Compensation

Options Compensation